Literature DB >> 29217518

Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation.

Tiffany Scully1, Carolyn D Scott1, Sue M Firth1, Lisa M Sedger2, John E Pintar3, Stephen M Twigg4, Robert C Baxter5.   

Abstract

Epidemiological studies show an association between obesity and poor breast cancer prognosis. We previously demonstrated that global IGFBP-3 deficiency, in IGFBP-3-null mice, resulted in a 50% reduction in mammary tumour growth over 3 weeks relative to tumours in wild-type (WT) C57BL/6 mice. This growth reduction was ameliorated by high fat feeding-induced obesity. This study aimed to examine how IGFBP-3 promotes tumour growth by influencing the immune tumour microenvironment in healthy and obese mice. Syngeneic EO771 cells, which lack detectable IGFBP-3 expression, were grown as orthotopic tumours in WT and IGFBP-3-null C57BL/6 mice placed on either a control chow or a high-fat diet (HFD), and examined by quantitative PCR and immunohistochemistry. In WT mice, increased stromal expression of IGFBP-3 was positively associated with tumour growth, supporting the hypothesis that IGFBP-3 in the microenvironment promotes tumour progression. Examining markers of immune cell subsets, gene expression of Ifng, Cd8a, Cd8b1 and Tnf and CD8 measured by immunohistochemistry were elevated in tumours of IGFBP-3-null mice compared to WT, indicating an accumulation of CD8+ T cells, but this increase was absent if the IGFBP-3-null mice had been exposed to HFD. Expression of these genes was negatively associated with tumour growth. Although similar among groups overall, Nkg2d and Tnfsf10 tumoural expression was associated with decreased tumour growth. Overall, the results of this study provide an immune-based mechanism by which host IGFBP-3 may promote breast tumour growth in the EO771 murine breast cancer model, and suggest that targeting IGFBP-3 might make a novel contribution to immune therapy for breast cancer.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  IGFBP-3; T cell; breast cancer; obesity; stroma

Mesh:

Substances:

Year:  2017        PMID: 29217518     DOI: 10.1530/ERC-17-0384

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  5 in total

1.  Nuclear Insulin-Like Growth Factor Binding Protein-3 As a Biomarker in Triple-Negative Breast Cancer Xenograft Tumors: Effect of Targeted Therapy and Comparison With Chemotherapy.

Authors:  Sohel M Julovi; Janet L Martin; Robert C Baxter
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-22       Impact factor: 5.555

2.  Clinical significance of serum IGFBP-3 in colorectal cancer.

Authors:  Yu-Lei Hou; Peng Luo; Guang-Yan Ji; Hui Chen
Journal:  J Clin Lab Anal       Date:  2019-06-19       Impact factor: 2.352

3.  Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway.

Authors:  Yadong Liu; Huiyan Lv; Xingyi Li; Jiannan Liu; Song Chen; Yaodong Chen; Yinshan Jin; Ruihua An; Shiliang Yu; Zhigang Wang
Journal:  Int J Biol Sci       Date:  2021-08-13       Impact factor: 6.580

Review 4.  The Immunomodulatory Role of Hypoxic Tumor-Derived Extracellular Vesicles.

Authors:  Joel E J Beaumont; Nicky A Beelen; Lotte Wieten; Kasper M A Rouschop
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

Review 5.  EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty.

Authors:  Augustin Le Naour; Adrien Rossary; Marie-Paule Vasson
Journal:  Cancer Med       Date:  2020-10-07       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.